

CURRICULUM VITAE



PERSONAL INFORMATION

Name Paolo Bossi
Address VIA DIAZ 19 – 21017 SAMARATE - VA
Telephone [REDACTED]
E-mail [REDACTED]
Nationality Italian
Tax code [REDACTED]
Date of birth MAY 31ST, 1975

WORK EXPERIENCE

- Dates (from – to) 12/2018- TO PRESENT
 - Name and address of employer University of Brescia
 - Type of business or sector Public Health
 - Occupation or position held Associate Professor of Medical Oncology
-
- Dates (from – to) 12/2005- 12/2018
 - Name and address of employer Prof. Lisa Licitra – Fondazione IRCCS “Istituto Nazionale Tumori”, Milano, Italy
 - Type of business or sector Public Health
 - Occupation or position held Medical oncologist
-
- Dates (from – to) 11/2001-11/2005
 - Name and address of employer Prof. AM Gianni, Postgraduate School of Oncology, Medical School, University, Milano, Italy
 - Type of business or sector Public Health
 - Occupation or position held Medical oncologist

EDUCATION AND TRAINING

- Dates (from – to) 4/11/2005
 - Name and type of organisation providing education and training University, Milano, Italy
 - Principal subjects/occupational Medical Oncology
 - Title of qualification awarded Postgraduate certificate in Clinical Oncologia (70/70 cum laude)
-
- Dates (from – to) 17/10/2001
 - Name and type of organisation providing education and training University, Milano, Italy
 - Title of qualification awarded Medical Degree (cum laude)

MOTHER TONGUE OTHER LANGUAGES

- ITALIAN
- English
Excellent
- Reading Writing Verbal skills

SCIENTIFIC SOCIETIES AFFILIATION AND TASKS

ESMO

EORTC Head and Neck Group

MASCC – Vice Chair of the Mucositis Study group for the period 2018-2021

AIOM (Italian Association of Medical Oncology)

AIOCC (Italian Association of head and Neck Oncology)

President of NICSO (Italian Network for Supportive Care in Oncology)

Board of Director of GONO (Gruppo Oncologico Nord Ovest)

Member of ESMO head and neck group and supportive and palliative care group

Member of the SIOG Task Force on the Quality of Life in Older Cancer Patients

BIOSKETCH

He is involved in all institutional research activities on **head and neck cancer**, from translational research (gene expression, next generation sequencing) to assessment of quality of life and value-based medicine. He is particularly dedicated to **rare cancer** among head and neck ones (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He has strong experience with medical treatment of non-melanoma skin cancer, designing and conducting trials with targeted therapy and immunotherapy. He has a strong commitment to **supportive care**, specifically for what concerns mucositis induced by cancer therapies. He collaborates to the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing to improve quality of care and diminish health migration for rare solid cancers. He is the Principal Investigator and co-investigator of several Italian and International trial on Head and Neck cancer and non-melanoma skin cancer.

PRIZES

2009: Clinical Young Researcher Award, by Fondazione Istituto Nazionale dei Tumori, Milan

2011: Clinical Young Researcher Award, by Fondazione Berlucci

2016: AIOM Award - Best project in Head and Neck multidisciplinary management

2016: Member of the ESMO leader generation program

2017: Member of the EORTC Early Career Investigators project

GRANTS

2011: Ministry of Health: Grant for development of targeted therapy in head and neck cancer

2014: Co-Investigator of the founded Swiss Bridge Prize, with the project: "Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients"

2014: Co-investigator of the founded Transcan Joint Transnational Call 2013, with the project: "A randomized phase II study for tertiary prevention of squamous cell cancer of head and neck (SCCHN) with a dietary intervention"

2015: Italian Association for Research on Cancer (AIRC):
Grant for translational research on paranasal sinus cancer

2018: Italian Association for Research on Cancer (AIRC):
Grant for translational research on predictors of response to immunotherapy in head and neck cancers, from oral premalignant lesions to recurrent/metastatic disease

2020: Grant for clinical trial on Vitamin D as prevention of SARS-Cov2 disease (R. Lombardia)

ANNEXES

List of Publications – Clinical trial participation – Organization of scientific conferences - Editorial Committee membership

I declare to have experience in good clinical practice and in study coordination.

I authorize the treatment of my personnel data, according to Italian laws (196/03) and art 13 GDPR 679/16

Brescia, October 10th, 2020

List of Publications Indexed on PubMed (total number = 202): H Index 35 (Scopus merged)

1. Locati LD, Quattrone P , **Bossi P**, Marchianò AV , Cantù G , Licitra L. "A complete remission with androgen deprivation therapy in a recurrent androgen receptors expressing adenocarcinoma of the parotid gland". **Ann Oncol**, 2003; **14 (8): 1327-8**.
2. Sanguineti G, **Bossi P**, Pou A, Licitra L. "Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma". **Clin Oncol**, 2003; **15: 451-60**.
3. Licitra L, **Bossi P**, Locati L, Zunino F. "Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?" **J Clin Oncol** 2004; **22: 377**
4. Licita L, Locati LD, **Bossi P**, Cantù G "Head and neck tumors other than squamous cell carcinomas" . **Curr Opin Oncol** 2004 May; **16: 236-41**
5. Palazzi M, Guzzo M, **Bossi P**, Tomatis S, Cerrotta A, Cantù G, Locati LD, Licitra L "Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy" . **Tumori** 2004; **90: 60-65**
6. Licitra L, Locati LD, **Bossi P**. "Head and neck cancer." **Ann Oncol** 2004; **15 Suppl 4: 267-73**.
7. Locati LD, Rinaldi G, **Bossi P**, Dagrada GP, Quattrone P, Cantù G, Licitra L. "Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer" **Oral Oncology** 2005; **41: 97-8**.
8. Licitra L, Suardi S, **Bossi P**, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantu G, Pierotti MA, Pilotti S "Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma." . **J Clin Oncol** 2004 **15; 22: 4901-6**.
9. Locati LD, Guzzo M, **Bossi P**, Massone PP, Conti B, Fumagalli E, Bareggi C, Cantu G, Licitra L. "Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland." **Oral Oncol**. 2005; **41: 890-4**.
10. Licitra L, **Bossi P**, D Locati L, Bergamini C. "Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?" **J Clin Oncol** 2005; **23: 7757-8**.
11. Licitra L, Rossini C, **Bossi P**, Locati LD. "Advances in the changing patterns of aetiology of head and neck cancers." **Curr Opin Otolaryngol Head Neck Surg** 2006; **14: 95-9**.
12. Licitra L, **Bossi P**, D Locati L. "A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?" **Curr Opin Oncol** 2006; **18: 253-7**.
13. **Licitra L**, Locati LD, BossiP. "Biological agents in head and neck cancer" **Ann Oncol** 2006; **17 suppl: x45-x48**
14. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, **Bossi P**, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S. "Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma". **Clin Cancer Res**. 2006; **12: 6643-51**.
15. Licitra L, Perrone F, **Bossi P**, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S. "How High-Risk Human Papillomavirus does affect prognosis of patients with oropharyngeal squamous cell carcinoma primarily treated by surgery". **J. Clin Oncol**. 2006; **24: 5630-36**.
16. **Bossi P**, Locati LD, Olmi P, Bergamini C, Liberatoscioli C, Licitra L "Previously irradiated areas spared from skin toxicity induced by cetuximab in 6 patients: implications for the administration of EGFR inhibitors in previously irradiated patients?" . **Ann. Oncol** 2006, **Oct 30**.

17. **Bossi P**, Locati LD, Licitra L. "Biological agents in head and neck cancer Expert Rev Anticancer Ther. 2007; 7: 1643-50
18. Perrone F, **Bossi P**, Licitra L "TP53 mutations in head and neck cancer".. **N Engl J Med. 2008; 358: 1194-5**
19. **Bossi P**, Locati LD, Licitra L, Tagliabue E. "Folate in head and neck squamous cell cancer chemoprevention: purposely left out?" **J Clin Oncol. 2008 Jul 10; 26:3463**
20. Licitra L, Locati LD, **Bossi P**. "Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options". **Ann Oncol. 2008 Sep;19 Suppl 7:vii200-3.**
21. Locati LD, **Bossi P**, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L "Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study". . **Oral Oncol. 2008 Sep 17.**
22. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabro E, Mancini A, Tosi D, **Bossi P**, Field JK, Brambilla E, Sozzi G "Fragile Histidine Triad Gene Inactivation in Lung Cancer: the European Early Lung Cancer Project." . **Am J Respir Crit Care Med. 2008 Dec 18**
23. Palazzi M, Orlandi E, **Bossi P**, Pignoli E, Potepan P, Guzzo M, Franceschini M, Scaramellini G, Cantù G, Licitra L, Olmi P, Tomatis S. "Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience" **Int J Radiat Oncol Biol Phys. 2009; 74: 774-80.**
24. Locati LD, Perrone F, Losa M, Mela M, Casieri P, Orsenigo M, Cortelazzi B, Negri T, Tamborini E, Quattrone P, **Bossi P**, Rinaldi G, Bergamini C, Calderone RG, Liberatoscioli C, Licitra L. "Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)." **Oral Oncol. 2009; 45: 986-90.**
25. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, **Bossi P**, Orlandi E, Palazzi M, Olmi P. "Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status." **Int J Radiat Oncol Biol Phys. 2009; 75:1053-9.**
26. Perrone F, **Bossi P**, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S, Licitra L. "TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma." **J Clin Oncol 2010; 28:761-6.**
27. Licitra L, Locati LD, Greco A, Granata R, **Bossi P**. "Multikinase inhibitors in thyroid cancer." **Eur J Cancer. 2010; 46:1012-8.**
28. **Bossi P**, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L "Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. . **Oral Oncol. 2010; 46: 888**
29. Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, **Bossi P**, Locati LD, Cantu' G, Scaramellini G, Pilotti S, Tagliabue E. "Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients." **Ann Oncol. 2011; 22:1886-93**
30. **Bossi P**, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. "Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer." **Ann Oncol. 2011 22: 2495-500**
31. Perrone F, Gloghini A, Cortelazzi B, **Bossi P**, Licitra L, Pilotti S "Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making." . **Am J Surg Pathol. 2011; 35: 774-7**

32. Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, **Bossi P**, Locati L, Schiavo R, Basso S, Baldanti F, Maccario R, Locatelli F, Siena S, Pedrazzoli P, Comoli P. "T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results." **Ann Oncol. 2012; 23: 435-41.**
33. Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, **Bossi P**, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L. "Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study." **Ann Oncol. 2012; 23:1832-7.**
34. **Bossi P**, Locati LD, Licitra L. Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. **J Clin Oncol. 2012; 30: 564-5.**
35. Locati LD, **Bossi P**, Licitra L How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma? **J Clin Oncol. 2012; 30: 672.**
36. **Bossi P**, Kornek G, Lanzetta G, Rozzi A, Füreder T, Locati L, Licitra L Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. **Head Neck. 2012; 35: 1471-4**
37. **Bossi P**, Resteghini C, Perrone F, Cortelazzi B, Pilotti S, Maurichi A, Locati LD, Licitra L. Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. **J Am Acad Dermatol. 2012; 67:e226-8.**
38. Orlandi E, Tomatis S, Potepan P, **Bossi P**, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai C. Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. **Future Oncol. 2013; 9: 103-14.**
39. **Bossi P**, Perrone F, Miceli R, Cantù G, Mariani L, Orlandi E, Fallai C, Locati LD, Cortelazzi B, Quattrone P, Potepan P, Licitra L, Pilotti S. Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. **Oral Oncol. 2013; 49:413-9.**
40. Orlandi E, **Bossi P**, Fallai C, Iannacone E, Licitra L. Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure" by Chan et Coll. **Oral Oncology 2013 Oct;49(10):e38**
41. Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M, **Bossi P**, Escalante C, Brennan MT; On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. **Support Care Cancer. 2013; 21: 3243-54**
42. Saunders DP, Epstein JB, Elad S, Allemano J, **Bossi P**, van de Wetering MD, Rao NG, Potting C, Cheng KK, Freidank A, Brennan MT, Bowen J, Dennis K, Lalla RV; For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. **Support Care Cancer. 2013; 21: 3191-207**
43. **Bossi P**, Locati LD, Licitra L. Emerging tyrosine kinase inhibitors for head and neck cancer. **Expert Opinion On Emerging Drugs 2013. 2013; 18: 445-59**
44. **Bossi P**, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, Locati L, Scaramellini G, Fallai C, Licitra L. Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. **Ann Oncol. 2014; 25: 462-6. doi: 10.1093/annonc/mdt555**
45. **Bossi P**, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, Locati L, Fallai C, Cortelazzi B, Pilotti S, Scaramellini G, Gloghini A, Licitra L. Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. **Ann Oncol. 2014; 25: 694-9. doi:10.1093/annonc/mdu004**

46. **Bossi P**, Numico G, De Santis V, Ruo Redda MG, Reali A, Belgioia L, Cossu Rocca M, Orlandi E, Airoidi M, Bacigalupo A, Mazzer M, Saibene G, Russi E. Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. **Support Care Cancer**. 2014 Feb 25.
47. Locati LD, Perrone F, Cortelazzi B, Imbimbo M, **Bossi P**, Potepan P, Civelli E, Rinaldi G, Quattrone P, Licitra L, Pilotti S. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. **Cancer Biol Ther**. 2014 Mar 11;15(6).
48. Ripamonti CI, **Bossi P**, Santini D, Fallon M. Pain related to cancer treatments and diagnostic procedures: a no man's land? **Ann Oncol**. 2014; 25:1097-106
49. De Cecco L, **Bossi P**, Locati L, Canevari S and Licitra L. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. **Annals of Oncology**, 2014; 25:1628-35
50. Granata R, **Bossi P**, Bertulli R, Saita L. Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. **Pain Med**. 2014 May;15(5):758-61
51. **Bossi P**, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, Licitra L. Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. **Oral Oncol**. 2014 Sep;50(9):884-7.
52. Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, **Bossi P**, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, Licitra L. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed AR-positive salivary gland cancers. **Head Neck**. 2014 Dec 18. doi: 10.1002/hed.23940.
53. Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, **Bossi P**, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, Licitra L, Pilotti S, Perrone F. Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. **J Oral Pathol Med**. 2014 Dec 14. doi: 10.1111/jop.12301.
54. Orlandi E, Takanen S, Giandini T, Iannacone E, Fontanella W, Locati L, Carrara M, **Bossi P**, Bergamini C, Granata R, Tombolini V, Ibbi T, Licitra L, Pignoli E, Fallai C. Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review **Future Oncol**. 2014 Nov;10(14):2111-20.
55. Orlandi E, Giandini T, Iannacone E, De Ponti E, Carrara M, Mongioj V, Stucchi C, Tana S, **Bossi P**, Licitra L, Fallai C, Pignoli E. Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy **Radiother Oncol**. 2014 Nov;113(2):260-6.
56. Saba NF, Haigentz M Jr, Vermorken JB, Strojanc P, **Bossi P**, Rinaldo A, Takes RP, Ferlito A. Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". **Oral Oncol**. 2015 Feb;51(2):112-8.
57. Roila F, Ripamonti CI, Antonuzzo A, **Bossi P** NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology. **Support Care Cancer**. 2015 Jan;23(1):11-2
58. Priol S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, **Bossi P**, Perrone F. Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. **Mol Oncol**. 2015 Feb;9(2):389-97.
59. Mirabile A, Numico G, Russi EG, **Bossi P**, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Mar 19. pii: S1040-8428

60. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, **Bossi P**, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. **Oncotarget**. 2015 Mar 20.
61. Greco A, Orlandi E, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, Licitra L, **Bossi P**. Italian version of the M.D. Anderson Symptom Inventory-Head and Neck Module: linguistic validation. **Support Care Cancer**. 2015 Mar 21.
62. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, **Bossi P**, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, Lee AW, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito A. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. **Head Neck**. 2015 Mar 3. doi: 10.1002/hed.24026
63. Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Alves MO, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, **Bossi P**, Kimmel M, Frederick MJ, Lichtarge O, Myers JN. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. **Cancer Res**. 2015 Apr 1;75(7):1205-15.
64. Mirabile A, Numico G, Russi EG, **Bossi P**, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Aug;95(2):191-213
65. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, **Bossi P**, Locati L, Licitra L, Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. **Oncotarget**. 2015 Apr 20;6(11):9627-42.
66. **Bossi P**, Lucchesi M, Antonuzzo A. Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. **Curr Opin Support Palliat Care**. 2015 Jun;9(2):163-7
67. Buzzacchino S, Lanzola G, **Bossi P**, Licitra L, Quaglini S. A mobile application supporting outpatient treatment and follow-up. **Stud Health Technol Inform**. 2015;210:788-92
68. Mirabile A, Vismara C, Crippa F, **Bossi P**, Locati L, Bergamini C, Granata R, Resteghini C, Conte E, Morelli D, Scarpellini P, Licitra L. Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. **Head Neck**. 2015 Jun 3.
69. Proserpio T, Ferrari A, Lo Vullo S, Massimino M, Clerici CA, Veneroni L, Bresciani C, Casali PG, Ferrari M, **Bossi P**, Galmozzi G, Pierantozzi A, Licitra L, Marceglia S, Mariani L. Hope in cancer patients: the relational domain as a crucial factor. **Tumori**. 2015 Jul-Aug;101(4):447-54.
70. Pessi MA, Necchi A, **Bossi P**, Resteghini C, Giannatempo P, Ferrari L, Zilembo N, Ripamonti CI. Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy. **Tumori**. 2015 Nov 14;101(6):692-6.
71. Schindler A, Denaro N, Russi EG, Pizzorni N, **Bossi P**, Merlotti A, Spadola Bissetti M, Numico G, Gava A, Orlandi E, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, Sanguineti G, Langendijk JA, Murphy B. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Nov;96(2):372-84.
72. Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, Numico G, **Bossi P**, Buglione M, Lombardo A, Airolidi M, Merlano MC, Licitra L, Denaro N, Pergolizzi S, Pinto C, Bensadoun RJ, Girolomoni G, Langendijk JA. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. **Crit Rev Oncol Hematol**. 2015 Oct;96(1):167-82.

73. **Bossi P**, Saba NF, Vermorken JB, Strojan P, Pala L, de Bree R, Rodrigo JP, Lopez F, Hanna EY, Haigentz M, Takes RP, Slootweg PJ, Silver CE, Rinaldo A, Ferlito A. The role of systemic therapy in the management of sinonasal cancer: A critical review. **Cancer Treat Rev.** 2015 Dec;**41(10):836-43**.
74. **Bossi P**, Orlandi E, Licitra L. Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. **Br J Cancer.** 2015 Dec **1;113(11):1638-9**
75. Buglione M, Cavagnini R, Di Rosario F, Sottocornola L, Maddalo M, Vassalli L, Grisanti S, Salgarello S, Orlandi E, Paganelli C, Majorana A, Gastaldi G, **Bossi P**, Berruti A, Pavanato G, Nicolai P, Maroldi R, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. **Crit Rev Oncol Hematol.** 2016 Jan;**97:131-42**.
76. Marta GN, Riera R, **Bossi P**, Zhong LP, Licitra L, Macedo CR, de Castro G Junior, Carvalho AL, William WN Jr, Kowalski LP. Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. **Eur J Cancer.** 2015 Nov;**51(17):2596-2603**. doi: 10.1016/j.ejca.2015.08.007.
77. **Bossi P**, Farina D, Gatta G, Lombardi D, Nicolai P, Orlandi E. Paranasal sinus cancer. **Crit Rev Oncol Hematol.** 2015 Oct 19. pii: S1040-8428(15)30049-4.
78. Castelnuovo P, Turri-Zanoni M, Battaglia P, Antognoni P, **Bossi P**, Locatelli D. Sinonasal Malignancies of Anterior Skull Base: Histology-driven Treatment Strategies. **Otolaryngol Clin North Am.** 2016 Feb;**49(1):183-200**.
79. Mirabile A, Airoidi M, Ripamonti C, Bolner A, Murphy B, Russi E, Numico G, Licitra L, **Bossi P**. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. **Crit Rev Oncol Hematol.** 2015 Dec 3. pii: S1040-8428(15)30081-0.
80. Bergamini C, Locati L, **Bossi P**, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, Orlandi E, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, Licitra L. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? **Oral Oncol.** 2016 Jan 13. pii: S1368-8375(16)00002-6.
81. Alfieri S, Ripamonti CI, Marceglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, **Bossi P**. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. **Head Neck.** 2016 Apr;**38 Suppl 1:E1521-7**. doi: 10.1002/hed.24272. Epub 2016 Feb 5. PubMed PMID: 26849016.
82. **Bossi P**, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, Locati LD, Licitra L, Canevari S, De Cecco L. Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab. **Clin Cancer Res.** 2016 Feb 26. pii: clincanres.2547.2015.
83. De Sanctis V, **Bossi P**, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendijk JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. **Crit Rev Oncol Hematol.** 2016 Apr;**100:147-66**. doi:10.1016/j.critrevonc.2016.01.010. Epub 2016 Feb 1. Review. PubMed PMID: 26947812.
84. Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, Licitra L, **Bossi P**. Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. **Tumori.** 2016 Mar **14:0**. doi: 10.5301/tj.5000485. PubMed PMID: 26979243.
85. **Bossi P**, Alfieri S. Investigational drugs for head and neck cancer. **Expert Opin Investig Drugs.** 2016 Jul;**25(7):797-810**. doi: 10.1080/13543784.2016.1175435. Epub 2016 Apr 25. PubMed PMID: 27054910.
86. Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, Salgarello S, Orlandi E, **Bossi P**, Majorana A, Gastaldi G, Berruti A, Trippa F, Nicolai P, Barasch A, Russi EG, Raber-Durlacher J, Murphy

B, Magrini SM. Oraltotoxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. **Crit Rev Oncol Hematol.** 2016 Jun;**102:47-54**. doi: 10.1016/j.critrevonc.2016.03.012. Epub 2016 Mar 11. Review. PubMed PMID:27061883.

87. **Bossi P**, Cortinovis D, Cossu Rocca M, Roila F, Seminara P, Fabi A, Canova S, Verri E, Fatigoni S, Iannace A, Macchi F, Ripamonti C. Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. **J Altern Complement Med.** 2016 Jun;**22(6):486-8**. doi:10.1089/acm.2015.0315. Epub 2016 Apr 26. PubMed PMID: 27115042; PubMed Central PMCID: PMC4921900.
88. Perrone F, **Bossi P**, Cortelazzi B, Dagrada GP, Paielli N, Licitra L, Pilotti S. Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. **Oral Oncol.** 2016 Jul;**58:e4-5**. doi: 10.1016/j.oraloncology.2016.05.015. Epub 2016 Jun 1. PubMed PMID: 27262592 .
89. Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, **Bossi P**, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS; Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. **Support Care Cancer.** 2016 Jun 25. [Epub ahead of print] Review. PubMed PMID: 27344327.
90. **Bossi P**, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. **Oncotarget.** 2016 Aug 19. doi: 10.18632/oncotarget.11413. [Epub ahead of print]
91. **Bossi P**, Alfieri S. The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. **Curr Treat Options Oncol.** 2016 Oct;**17(10):53**.
92. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordóñez B, Weinreb I, **Bossi P**, Orlandi E, Licitra LF, Song Y, O'Sullivan B, Siu LL, Kim J. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. **Eur J Cancer.** 2016 ;**67:174-182**
93. **Bossi P**, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. **Int J Radiat Oncol Biol Phys.** 2016 ;**96:959-966**.
94. Locati LD, Perrone F, Cortelazzi B, Bergamini C, **Bossi P**, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. **Eur J Cancer.** 2016;**69:158-165**.
95. Valenti C, Pozzi P, Busia A, Mazza R, **Bossi P**, De Marco C, Ruprecht AA, Borgini A, Boffi R. Respiratory illness and air pollution from the steel industry: the case of Piquiá de Baixo, Brazil (Preliminary report). **Multidiscip Respir Med.** 9;**11:41**
96. Orlandi E, **Bossi P**. Towards a personalized cancer care for elderly head and neck cancer patients. **Int J Radiat Oncol Biol Phys.** 2017 Jul 15;**98(4):965-966**.
97. De Cecco L, Giannoccaro M, Marchesi E, **Bossi P**, Favales F, Locati LD, Licitra L, Pilotti S, Canevari S. Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. **Genes** (Basel). 2017; 8(1). pii: E35. doi: 10.3390/genes8010035.
98. Iacovelli NA, Naimo S, Bonfantini F, Cavallo A, **Bossi P**, Fallai C, Pignoli E, Alfieri S, Bergamini C, Favales F, Orlandi E. Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. **Support Care Cancer.** 2017 doi: 10.1007/s00520-017-3569-z

99. Alfieri S, Granata R, Bergamini C, Resteghini C, **Bossi P**, Licitra LF, Locati LD. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? **Oral Oncol**. 2017 Mar;66:58-63.
100. Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, Locati L, Licitra L, **Bossi P**. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. **Oral Oncol**. 2017 Jun;69:33-37
101. Alfieri S, Iacovelli NA, Marcegaglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, **Bossi P**. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. **Oncotarget**. 2017 May 11. doi:10.18632/oncotarget.17822
102. Meregaglia M, Cairns J, Alfieri S, Favales F, Mazzitelli D, Orlandi E, Licitra L, **Bossi P**. Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. **Value Health**. 2017 Jun;20(6):799-808
103. **Bossi P**, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high dose cisplatin. **Ann Oncol**. 2017 Jun 28. doi: 10.1093/annonc/mdx315
104. **Bossi P**, Cossu Rocca M, Corvò R, Depenni R, Guardamagna V, Marinangeli F, Miccichè F, Trippa F. The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. **Crit Rev Oncol Hematol**. 2017 Aug;116:82-88.
105. Zini EM, Lanzola G, **Bossi P**, Quaglini S. An Environment for Guideline-based Decision Support Systems for Outpatients Monitoring. **Methods Inf Med**. 2017 Aug 11;56(4):283-293.
106. Resteghini C, Locati LD, **Bossi P**, Bergamini C, Guzzo M, Licitra L. Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding. **Ann Oncol**. 2017 Sep 1;28(9):2321-2322
107. Resteghini C, Cavaliere S, Galbiati D, Granata R, Alfieri S, Bergamini C, **Bossi P**, Licitra L, Locati LD. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. **Best Pract Res Clin Endocrinol Metab**. 2017 Jun;31(3):349-361
108. **Bossi P**, Miceli R, Locati LD, Ferrari D, Vecchio S, Moretti G, Denaro N, Caponigro F, Moro C, Vaccher E, Sponghini A, Caldara A, Rinaldi G, Ferrau F, Nolè F, Lo Vullo S, Tettamanzi F, Hollander L, Licitra L. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. **Ann Oncol**. 2017 Sep 8. doi: 10.1093/annonc/mdx439
109. Alfieri S, Orlandi E, **Bossi P**. The Case Volume Issue in Head and Neck Oncology. **Curr Treat Options Oncol**. 2017 Oct 27;18(11):65
110. Resteghini C, Alfieri S, Quattrone P, Dominoni F, Garzone G, Orlandi E, Locati L, Bergamini C, Galbiati D, Iacovelli NA, Fallai C, Licitra L, **Bossi P**. RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target? **Oncotarget**. 2017 Oct 16;8(56):96184-96189.
111. Alfieri S, Bergamini C, Granata R, Locati L, Licitra L, **Bossi P**. Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. **Target Oncol**. 2017 Dec 12. doi: 10.1007/s11523-017-0545-
112. **Bossi P**, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, Locati LD, Canevari S, Licitra L, De Cecco L. Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? **Dis Markers**. 2017;2017:6870614.

113. Machiels JP, **Bossi P**, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF. Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). *Ann Oncol*. 2018 Jan 15. doi: 10.1093/annonc/mdy013
114. **Bossi P**, Granata R, Orlandi E, Licitra L. Comment on 'Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer'. *Br J Cancer*. 2018 Feb 6;118(3):e5. doi: 10.1038/bjc.2017.416.
115. **Bossi P**, Miceli R, Granata R, Naimo S, Infante G, Locati LD, Iacovelli NA, Fallai C, Licitra L, Orlandi E. Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. *Int J Radiat Oncol Biol Phys*. 2018 Apr 1;100(5):1217-1221. doi: 10.1016/j.ijrobp.2017.12.281.
116. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martinez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, **Bossi P**, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. *ESMO Open*. 2018 Feb 2;3(2):e000285.
117. Meregaglia M, Cairns J, Licitra L, **Bossi P**. The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. *Eur J Cancer*. 2018 Apr;93:89-98. doi: 10.1016/j.ejca.2018.01.082. Epub 2018 Mar 20.
118. Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, **Bossi P**. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. *Cancer Treat Rev*. 2018 Apr;65:78-86. doi: 10.1016/j.ctrv.2018.03.003.
119. Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, **Bossi P**, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):379-385. doi: 10.1080/17425255.2018.1461839
120. Iqbal MS, Dua D, Kelly C, **Bossi P**. Managing older patients with head and neck cancer: The non-surgical curative approach. *J Geriatr Oncol*. 2018 Jul;9(4):411-417. doi: 10.1016/j.jgo.2018.03.016
121. Cavalieri S, Perrone F, Miceli R, Ascierio PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, **Bossi P**. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004
122. Rauh S, Antonuzzo A, **Bossi P**, Eckert R, Fallon M, Fröbe A, Gonella S, Giusti R, Lakatos G, Santini D, Villarini A. Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. *ESMO Open*. 2018 May 5;3(4):e000345. doi: 10.1136/esmoopen-2018-000345.
123. Ripamonti CI, Antonuzzo A, **Bossi P**, Cavalieri S, Roila F, Fatigoni S. Fatigue, a major still underestimated issue. *Curr Opin Oncol*. 2018 Jul;30(4):219-225. doi: 10.1097/CCO.0000000000000451.
124. Siano M, Espeli V, Mach N, **Bossi P**, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncol*. 2018 Jul;82:144-151. doi: 10.1016/j.oraloncology.2018.05.013
125. **Bossi P**, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, Schuler U, Snegovoy A, Jordan K, Ripamonti CI. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines.; ESMO Guidelines Committee. *Ann Oncol*. 2018 Jun 21. doi: 10.1093/annonc/mdy145.
126. Orlandi E, Miceli R, Infante G, Mirabile A, Alterio D, Cossu Rocca M, Denaro N, Vigna-Taglianti R, Merlotti A, Schindler A, Pizzorni N, Fallai C, Licitra L, **Bossi P**. Predictors of Patient-Reported Dysphagia Following

127. Scotté F, **Bossi P**, Carola E, Cudenneq T, Dielenseger P, Gomes F, Knox S, Strasser F. Addressing the quality of life needs of older patients with cancer: A SIOG consensus paper and practical guide. *Ann Oncol*. 2018 Jul 13. doi: 10.1093/annonc/mdy228.
128. Giusti R, **Bossi P**, Mazzotta M, Filetti M, Iacono D, Marchetti P. The use of fentanyl in pain management in head and neck cancer patients: a narrative review. *Br J Pain*. 2018 Aug;12(3):155-162.
129. **Bossi P**, Miceli R, Granata R, Naimo S, Infante G, Locati LD, Iacovelli NA, Fallai C, Orlandi E, Licitra L. In Reply to Fakhry et al. *Int J Radiat Oncol Biol Phys*. 2018 Nov 1;102(3):670-67
130. Orlandi E, Iacovelli NA, Rancati T, Cicchetti A, **Bossi P**, Pignoli E, Bergamini C, Licitra L, Fallai C, Valdagni R, Cavallo A. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. *Oral Oncol*. 2018 Nov;86:266-272
131. **Bossi P**. Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer? *ESMO Open*. 2018 Oct 24;3(6):e000449
132. **Bossi P**, Miceli R, Benasso M, Corvò R, Bacigalupo A, Sanguineti G, Fallai C, Merlano MC, Infante G, Dani C, Di Giannantonio V, Licitra L. Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. *Head Neck*. 2018 Nov 17
133. Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, **Bossi P**, Alfieri S, Serafini G, Colombo CB, Cicchetti A, Mira M, Licitra L, Fallai C, Crippa F, Orlandi E. Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. *Radiol Med*. 2018 Dec 17.
134. Mirabile A, Miceli R, Calderone RG, Locati L, **Bossi P**, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. *Head Neck*. 2019. doi: 10.1002/hed.25636. [Epub ahead of print]
135. Mennini FS, Marcellusi A, Fabiano G, Platini F, **Bossi P**. Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. *Head Neck*. 2019;41(4):908-914. doi: 10.1002/hed.25481.
136. Szturz P, **Bossi P**, Vermorken JB. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. *Curr Opin Otolaryngol Head Neck Surg*. 2019 Apr;27(2):142-150
137. **Bossi P**, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, Orlandi E, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI. Prevalence of Fatigue in Head and Neck Cancer Survivors. *Ann Otol Rhinol Laryngol*. 2019 May;128(5):413-419. doi: 10.1177/0003489419826138
138. Coca-Pelaz A, Halmos GB, Strojanc P, de Bree R, **Bossi P**, Bradford CR, Rinaldo A, Vander Poorten V, Sanabria A, Takes RP, Ferlito A. The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. *Head Neck*. 2019 Feb 9. doi: 10.1002/hed.25696
139. De Cecco L, Serafini MS, Facco C, Granata R, Orlandi E, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, **Bossi P**. A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. *Oral Oncol*. 2019. doi: 10.1016/j.oraloncology.2019.02.003
140. Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, **Bossi P**, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? *Expert Opin Investig Drugs*. 2019. doi:10.1080/13543784.2019.1598376.
141. **Bossi P**, Alfieri S, Strojanc P, Takes RP, López F, Mäkitie A, Saba NF, Rodrigo JP, Bradford C, Suarez C, Zafereo M, Forastiere AA, Vermorken JB, Quer M, Sanabria A, Simo R, de Bree R, Rinaldo A, Ferlito A. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. *Crit Rev Oncol Hematol*. 2019 May;137:84-91

142. Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, **Bossi P**, Perrone F. Identification of potentially druggable molecular alterations in skin adnexal malignancies. *J Dermatol*. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889.
143. Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolè F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, **Bossi P**. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. *Eur J Cancer*. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022.
144. **Bossi P**, Giusti R, Tarsitano A, Airoidi M, De Sanctis V, Caspiani O, Alterio D, Tartaro T, Alfieri S, Siano M. The point of pain in head and neck cancer. *Crit Rev Oncol Hematol*. 2019 Jun;138:51-59.
145. Cavalieri S, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, **Bossi P**. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. *Oncology*. 2019;97(2):112-118. doi: 10.1159/000500246
146. Mattavelli D, Lombardi D, Missale F, Calza S, Battocchio S, Paderno A, Bozzola A, **Bossi P**, Vermi W, Piazza C, Nicolai P. Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio. *Front Oncol*. 2019 Apr 30;9:339. doi: 10.3389/fonc.2019.00339.
147. **Bossi P**, Seront E, Machiels JP. May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer? *Oral Oncol*. 2019 Jul;94:121-122. doi:10.1016/j.oraloncology.2019.05.011.
148. **Bossi P**, Botta L, Bironzo P, Sonetto C, Musettini G, Sbrana A, Di Giannantonio V, Locati LD, Di Maio M, Antonuzzo A. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. *Future Oncol*. 2019 Jul;15(21):2543-2553. doi: 10.2217/fon-2018-0772
149. Ranna V, Cheng KKF, Castillo DA, Porcello L, Vaddi A, Lalla RV, **Bossi P**, Elad S; Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. Mucositis Study group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04891-1.
150. Zadik Y, Arany PR, Fregnani ER, **Bossi P**, Antunes HS, Bensadoun RJ, Gueiros LA, Majorana A, Nair RG, Ranna V, Tissing WJE, Vaddi A, Lubart R, Migliorati CA, Lalla RV, Cheng KKF, Elad S; Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04890-2.
151. Yarom N, Hovan A, **Bossi P**, Ariyawardana A, Jensen SB, Gobbo M, Saca-Hazboun H, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr NM, Rouleau T, Lucas AS, Treister NS, Zur E, Ranna V, Vaddi A, Cheng KKF, Barasch A, Lalla RV, Elad S. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer / International Society of Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04887-x.
152. Ariyawardana A, Cheng KKF, Kandwal A, Tilly V, Al-Azri AR, Galiti D, Chiang K, Vaddi A, Ranna V, Nicolatou-Galitis O, Lalla RV, **Bossi P**, Elad S. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04888-w.
153. Bowen J, Al-Dasooqi N, **Bossi P**, Wardill H, Van Sebille Y, Al-Azri A, Bateman E, Correa ME, Raber-Durlacher J, Kandwal A, Mayo B, Nair RG, Stringer A, Ten Bohmer K, Thorpe D, Lalla RV, Sonis S, Cheng K, Elad S; The pathogenesis of mucositis: updated perspectives and emerging targets. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04893-z.

154. Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, Fall-Dickson JM, Johansen J, Ameringer S, Kataoka T, Weikel D, Eilers J, Ranna V, Vaddi A, Lalla RV, **Bossi P**, Elad S; Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04848-4.
155. Bowen JM, Gibson RJ, Collier JK, Blijlevens N, **Bossi P**, Al-Dasooqi N, Bateman EH, Chiang K, de Mooij C, Mayo B, Stringer AM, Tissing W, Wardill HR, van Sebille YZA, Ranna V, Vaddi A, Keefe DM, Lalla RV, Cheng KKF, Elad S; Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). *Support Care Cancer*. 2019 Jul 8. doi: 10.1007/s00520-019-04892-0
156. Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, **Bossi P**. Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. *Otolaryngol Head Neck Surg*. 2019 Jul 9:194599819860808
157. Orlandi E, Iacovelli NA, Cavallo A, Resteghini C, Gandola L, Licitra L, **Bossi P**. Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression? *Head Neck*. 2019 Jul 17. doi: 10.1002/hed.25848.
158. Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, **Bossi P**, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. *Head Neck*. 2019 Jul 29. doi: 10.1002/hed.25891
159. Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghini C, Cavalieri S, **Bossi P**, Canevari S, Licitra L, De Cecco L. Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2019 Jul 26;11(8). pii: E1057. doi: 10.3390/cancers11081057.
160. Orlandi E, Cavalieri S, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, **Bossi P**. Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. *Laryngoscope*. 2019 Aug 1. doi: 10.1002/lary.28202.
161. Mozzanica F, Scarponi L, Rota M, Succo G, Crosetti E, Guzzo M, **Bossi P**, Piazza C, Ottaviani F, Schindler A. Psychometric properties of the Italian version of the Speech Handicap Index. *Disabil Rehabil*. 2019 Aug 23:1-6
162. Zini EM, Lanzola G, Quaglini S, **Bossi P**, Licitra L, Resteghini C. A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. *Int J Med Inform*. 2019 Sep;129:404-412
163. Ferella L, Cavallo A, Miceli R, Iacovelli NA, Giandini T, Pignoli E, Calareso G, **Bossi P**, Resteghini C, Gravina GL, Nicolai P, Castelnuovo P, Piazza C, Licitra L, Fallai C, Orlandi E. Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. *Tumori*. 2019 Aug 27:300891619868006. doi: 10.1177/0300891619868006
164. Merlano M, Denaro N, Benasso M, Licitra L, **Bossi P**, Locati L, Vecchio S, Bruzzi P. Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. *Oral Oncol*. 2019 Oct;97:99-104. doi: 10.1016/j.oraloncology.2019.08.019.
165. Ivaldi E, Di Mario D, Paderno A, Piazza C, **Bossi P**, Iacovelli NA, Incandela F, Locati L, Fallai C, Orlandi E. Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. *Crit Rev Oncol Hematol*. 2019 Nov;143:67-75. doi: 10.1016/j.critrevonc.2019.08.003

166. Iqbal MS, Wilkinson D, Tin A, **Bossi P**, Gradwell-Nelson L, Kovarik J, O'Hara J, Kelly C. Cetuximab in the management of nasopharyngeal carcinoma - a narrative review. *J Laryngol Otol*. 2019 Sep 11;1-13. doi: 10.1017/S0022215119001853.
167. Bonomo P, Paderno A, Mattavelli D, Zenda S, Cavalieri S, **Bossi P**. Quality Assessment in Supportive Care in Head and Neck Cancer. *Front Oncol*. 2019 Sep 18;9:926. doi: 10.3389/fonc.2019.00926.
168. Rognoni C, Quaglini S, Vermorken JB, De Cecco L, Licitra L, **Bossi P**. Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. *Clin Ther*. 2019 Dec;41(12):2517-2528.e28. doi: 10.1016/j.clinthera.2019.09.015
169. Giralt J, Tao Y, Kortmann RD, Zasadny X, Contreras-Martinez J, Ceruse P, Arias de la Vega F, Lalla RV, Ozsahin EM, Pajkos G, Mazar A, Attali P, **Bossi P**, Vasseur B, Sonis S, Henke M, Bensadoun RJ. Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2019 Oct 25. pii: S0360-3016(19)33905-7. doi: 10.1016/j.ijrobp.2019.10.023
170. Saba NF, Chen ZG, Haigentz M, **Bossi P**, Rinaldo A, Rodrigo JP, Mäkitie AA, Takes RP, Strojan P, Vermorken JB, Ferlito A. Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. *Mol Cancer Ther*. 2019 Nov;18(11):1909-1915. doi: 10.1158/1535-7163.
171. Mesia R, **Bossi P**, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. *Eur J Cancer*. 2019 Dec;123:138-145. doi: 10.1016/j.ejca.2019.10.002
172. **Bossi P**, Ghiani M, Argenone A, Depenni R. Is pain part of a systemic syndrome in head and neck cancer? *Support Care Cancer*. 2019 Nov 12. doi: 10.1007/s00520-019-05147-8.
173. Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, Potting C, Rouleau T, Toro JJ, Ranna V, Vaddi A, Peterson DE, **Bossi P**, Lalla RV, Elad S. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer*. 2019 Dec 14. doi: 10.1007/s00520-019-05217-x.
174. Ferrari M, **Bossi P**, Mattavelli D, Ardighieri L, Nicolai P. Management of sinonasal adenocarcinomas with anterior skull base extension. *J Neurooncol*. 2020 Jan 3. doi: 10.1007/s11060-019-03385-8
175. **Bossi P**, Airoidi M, Aloe Spiriti MA, Antonuzzo A, Bonciarelli G, Campagna A, Cassano A, Murialdo R, Musio D, Silvano G. A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. *Expert Opin Drug Saf*. 2020 Feb;19(2):187-204.
176. Bologna M, Calareso G, Resteghini C, Sdao S, Montin E, Corino V, Mainardi L, Licitra L, **Bossi P**. Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer. *NMR Biomed*. 2020 Feb 3:e4265
177. Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, **Bossi P**, Orlandi E, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. *Cancer*. 2020 Jan 1;126(9):1888-1894
178. Saunders DP, Rouleau T, Cheng K, Yarom N, Kandwal A, Joy J, Bektas Kayhan K, van de Wetering M, Brito-Dellan N, Kataoka T, Chiang K, Ranna V, Vaddi A, Epstein J, Lalla RV, **Bossi P**, Elad S; Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer*. 2020 May;28(5):2473-2484
179. Yarom N, Hovan A, **Bossi P**, Ariyawardana A, Jensen SB, Gobbo M, Saca-Hazboun H, Kandwal A, Majorana A, Ottaviani G, Pentenero M, Nasr NM, Rouleau T, Lucas AS, Treister NS, Zur E, Ranna V, Vaddi A, Barasch A, Lalla RV, Cheng KKF, Elad S. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2:

honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. *Support Care Cancer*. 2020 May;28(5):2457-2472.

180. Logan RM, Al-Azri AR, **Bossi P**, Stringer AM, Joy JK, Soga Y, Ranna V, Vaddi A, Raber-Durlacher JE, Lalla RV, Cheng KKF, Elad S. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer*. 2020 May;28(5):2485-2498.
181. Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati L, Giacomelli L, Licitra L, **Bossi P**. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. *Drugs Context*. 2019 Dec 19;8:212611
182. Antonuzzo A, Calabrò F, Quaglino P, Roila F, Sebastiani GD, Spina F, Pasqualetti G, Cortinovis D, Tagliaferri E, Peri A, Presotto EM, Egidi MF, Giacomelli L, Farroni F, Di Maio M, De Luca E, Danova M, Scottè F, Jordan K, **Bossi P**. Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. *Network Italiano Cure di Supporto in Oncologia (NICSO)*. *Oncologist*. 2020 Jun;25(6):e946-e954.
183. Alfieri S, Carezzo A, Platini F, Serafini MS, Perrone F, Galbiati D, Sponghini AP, Depenni R, Vingiani A, Quattrone P, Marchesi E, Iannò MF, Micali A, Mancinelli E, Orlandi E, Marcegaglia S, Locati LD, Licitra L, **Bossi P**, De Cecco L. Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2020 Apr 9;12(4):922.
184. Ferrari M, Ioppi A, Schreiber A, Gualtieri T, Mattavelli D, Rampinelli V, Taboni S, Tomasoni M, **Bossi P**, Deganello A, Nicolai P. Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients. *Oral Oncol*. 2020 Jul;106:104672.
185. **Bossi P**, Hermsen M, Lechner M, Franchi A. Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm. *Oral Oncol*. 2020 Oct;109:104737.
186. Milione M, Maisonneuve P, Grillo F, Mangogna A, Centonze G, Prinzi N, Pusceddu S, Garzone G, Cattaneo L, Busico A, **Bossi P**, Spaggiari P, Pellegrinelli A, Del Gobbo A, Ferrero S, Kankava K, Pruneri G, Rolli L, Roca E, Bercich L, Tironi A, Benvenuti MR, Gallazzi MS, Romano R, Berruti A, Pastorino U, Capella C. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. *Neuroendocrinology*. 2020 May 4. doi: 10.1159/000508376
187. **Bossi P**, Peris K, Calzavara-Pinton P, Queirolo P, Alfieri S, Palla M, Rossi MT, Spagnolo F, Tambone S, Astolfi C, Ascierto PA Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. *Future Oncol*. 2020 Jun;16(16):1091-1100
188. Apro M, **Bossi P**, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. *Support Care Cancer*. 2020 Oct;28(10):4589-4612.
189. Wardill HR, Sonis ST, Blijlevens NMA, Van Sebille YZA, Ciorba MA, Loeffen EAH, Cheng KKF, **Bossi P**, Porcello L, Castillo DA, Elad S, Bowen JM; Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. *Support Care Cancer*. 2020 Nov;28(11):5059-5073.
190. Guglielmo M, Di Pede P, Alfieri S, Bergamini C, Platini F, Ripamonti CI, Orlandi E, Iacovelli NA, Licitra L, Maddalo M, **Bossi P**. A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. *J Cancer Res Clin Oncol*. 2020 Oct;146(10):2479-2487
191. Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Lo Vullo S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Calareso G, Clement P, Hauben E, Platini F, **Bossi P**, Licitra L, Locati LD. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. *Eur J Cancer*. 2020 Sep;136:35-42

192. Takes RP, Halmos GB, Ridge JA, **Bossi P**, Merx MAW, Rinaldo A, Sanabria A, Smeele LE, Mäkitie AA, Ferlito A. Value and Quality of Care in Head and Neck Oncology. *Curr Oncol Rep.* 2020 Jul 10;22(9):92
193. Orlandi E, Iacovelli NA, Ingargiola R, Resteghini C, **Bossi P**, Licitra L, Ferrari M, Nicolai P. Treatment Options for Recurrent Anterior Skull Base Tumors. *Adv Otorhinolaryngol.* 2020;84:231-245.
194. Nicolai P, Bradley PJ, **Bossi P**, Ferrari M. Future Perspectives in the Management of Tumors of the Anterior Skull Base. *Adv Otorhinolaryngol.* 2020;84:246-250
195. Licitra L, Resteghini C, **Bossi P**. The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. *Adv Otorhinolaryngol.* 2020;84:78-86
196. Ravanelli M, Grammatica A, Maddalo M, Ramanzin M, Agazzi GM, Tononcelli E, Battocchio S, **Bossi P**, Vezzoli M, Maroldi R, Farina D. Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation. *AJNR Am J Neuroradiol.* 2020 Aug;41(8):1473-1479
197. Mattavelli D, Ferrari M, Taboni S, Morello R, Paderno A, Rampinelli V, Del Bon F, Lombardi D, Grammatica A, **Bossi P**, Deganello A, Piazza C, Nicolai P. The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing. *Oral Oncol.* 2020 Aug 1;111:104937.
198. Careno A, Serafini MS, Roca E, Paderno A, Mattavelli D, Romani C, Saintigny P, Koljenović S, Licitra L, De Cecco L, **Bossi P**. Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. *Cells.* 2020 Aug 3;9(8):1828.
199. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, **Bossi P**. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). *Cancer.* 2020 Jul 28;126(19):4423-31.
200. Ingargiola R, De Santis MC, Iacovelli NA, Facchinetti N, Cavallo A, Ivaldi E, Dispinziersi M, Franceschini M, Giandini C, Romanello DA, Di Biaso S, Sabetti M, Locati L, Alfieri S, **Bossi P**, Guglielmo M, Macchi F, Lozza L, Valdagni R, Fallai C, Pignoli E, Orlandi E. A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. *Radiat Oncol.* 2020 Aug 13;15(1):193
201. Antonuzzo A, **Bossi P**, Cortinovis D. Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action. *Ann Oncol.* 2020 Oct;31(10):1289-1290
202. Dalla Volta A, Valcamonico F, Pedersini R, Fornaro C, Tovazzi V, Monteverdi S, Baggi A, Consoli F, Ferrari VD, Grisanti S, Conti E, Amoroso V, **Bossi P**, Berruti A. The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. *Front Oncol.* 2020 Aug 18;10:1574.

Book chapters:

“Oropharyngeal cancers”

Licitra L, **Bossi P**, Locati L et al. in “Head & Neck surgery”, Jaypee Brothers Medical Publishers 2009: 970-977

“Oropharyngeal cancers” .

.Licitra L, **Bossi P**, Locati L, Cantú G, Olmi P.

In: Textbook of Medical Oncology. Editors: Cavalli F, Hansen HH, Kaye SB. 2009.

“Role of HPV infections in head and neck cancer”

Licitra L, Locati LD, Bergamini C, **Bossi P**. Editor: Robert Haddad, 2011

“Carcinoma del rinofaringe”

Orlandi E, **Bossi P**. Tumori della testa e del collo. Editor: Lisa Licitra, Patrizia Olmi, 2011

“Carcinoma dei seni paranasali”

Paolo Castelnuovo, Maurizio Bignami, Paolo Battaglia, Stefania Gallo, Pietro Gabriele, Elisabetta Garibaldi, Barbara Carau, **Paolo Bossi**. Tumori della testa e del collo. Editor: Lisa Licitra, Patrizia Olmi, 2011

“Role of chemotherapy in thyroid cancer”

Bossi P, Locati LD. In “Thyroid cancer: from emergent biotechnologies to clinical practice guidelines” ed. Carpi A, Mechanick JI. CRC press 2011; 313-318

“Thyroid cancer”

Locati LD, Greco A, Borrello MG, **Bossi P**. et al. in “Biotargets of cancer in current clinical practice”, ed. Springer, 2012: 61-91

“Oropharyngeal cancers”

Locati LD, **Bossi P**, Fallai C, Licitra L in “Head & Neck surgery”, Jaypee Brothers Medical Publishers updated for the new edition 2013

“Neoplasie del distretto cervico-facciale”.

Licitra L, **Bossi P**, Locati L.D.

In Medicina Oncologica. Editori: Labianca Roberto e Cascinu Stefano. Edra 2013

“Rehabilitation issues during cancer treatment and follow-up”

Ripamonti C.I. and **Bossi P**.

ESMO Handbook Series edited by Henk van Halteren. 2014.

“Manuale di cure di supporto in oncologia”.

Bossi P.

Editor on behalf of Nicso (Network di cure di supporto in oncologia). Società Editrice Universo 2015.

“Head and Neck Cancers and Neuro-oncology. Essential for clinicians”. Individualized supportive care before and during curative treatment. **Bossi P**.

Edited by Lisa Licitra and Michalis Karamouzis. ESMO 2017

Teaching activity:

- ✓ Internal medicine course. Nurse Degree. Università degli studi di Milano. 2016/2017; 2017/2018
- ✓ University of Brescia: teaching activity in Oncology Courses
- ✓ Thesis advisor to 10 candidates

Editorial Board of:

- ✓ Head and neck cancer section - Annals of Oncology 2013-2015
- ✓ ESMO Open 2017 – today
- ✓ Frontiers in Oncology 2019-today

CLINICAL TRIALS

In the last 2 years (2018-2020): Principal Investigator of 20 clinical trials and co-PI/subPI of other 45 trials.

As PI, he received grants for Investigator Initiated Trials from :

- MSD, for the trial « Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) »
- MSD for the trial « Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer »
- GSK for the trial « Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) »
- SunPharma for the trial « A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (BCC) – the SONIBEC trial »

- Kyowa Kyrin for the trial « Granisetron transdermal system (gtds) in preventing nausea and vomiting induced by cisplatin-based chemotherapy and concurrent radiotherapy for head and neck cancer »
- Amgen for the trial « Denosumab in ebv related nasopharyngeal carcinoma (npc) as a model for rank-mediated immunologic modulation of virus-related tumours -dern study »

ORGANIZATION OF SCIENTIFIC MEETINGS :

- 2014 : Scientific Committee of the « Consensus conference on supportive care during curative treatment with radiochemotherapy for head and neck cancer patients »
- 2015 : Scientific Committee of the « Nasopharyngeal cancer seminar »
- 2016 : Scientific Committee of the « Consensus conference on management of supportive care needs for patients with recurrent or metastatic head and neck cancer »
- 2016 : Scientific Committee of the « Multidisciplinary Seminar on Paranasal sinus cancer »
- 2014 and 2015 : Scientific Committee of the Forum for Supportive Care in Oncology (Rome and Milano)
- 2015, 2016, 2017, 2018, 2019, 2020 : Scientific Committee of the « Grandangolo in terapie di supporto » (Bologna)
- 2017 : Scientific Committee of the « Seminar for the multidisciplinary approach to elderly cancer patients »
- 2019 : Scientific Committee of the « Methodology in rare cancer trials »
- 2019 : Scientific Committee of the « Approaches to head and neck cancer treatment » congress

Brescia, October 10th, 2020

